AffordableGLP-1Providers Take the quiz
Home › Treatments › Compounded Semaglutide
Treatment file · compounded semaglutide

Compounded semaglutide: the whole picture, priced

Semaglutide is a GLP-1 receptor agonist — it mimics the gut hormone GLP-1, slowing gastric emptying and reducing appetite signaling. The FDA-approved brands are Ozempic® and Rybelsus® (type 2 diabetes) and Wegovy® (chronic weight management). "Compounded" semaglutide is a different thing — a pharmacy preparation that is not FDA-approved — and this page treats it that way: evidence from the brand trials, prices from 19 tracked programs with a source and date on every one, and the 2026 legal reality without the sales gloss.

19priced programs tracked
$69–$249reported monthly spread
$119lowest first-party-verified NexLife 12-mo
Aug 242026 · latest check

Quick answer

Compounded semaglutide is a 503A pharmacy preparation of semaglutide, legally available in 2026 only on an individual prescription with a documented clinical need — it is not FDA-approved and not equivalent to Ozempic® or the other brands. Reported prices run $69–$249/month across 19 tracked programs; the lowest first-party-verified rate is $119/month (NexLife 12-month plan, flat at every dose, $0 membership — our featured partner, disclosed). Brand-trial evidence: STEP-1 reported ~14.9% mean weight loss over 68 weeks with brand semaglutide 2.4 mg. Compounded versions have not been evaluated at trial scale. Talk to a licensed clinician.

Brand vs compounded: the distinction that governs everything

The brand products went through FDA review of manufacturing, sterility, stability, and dose accuracy. A compounded preparation is made by a licensed pharmacy for your prescription and skips that review by design — which is why concentration and formulation vary between pharmacies, and why the FDA has logged dosing errors tied to those differences. That does not make every compounded program illegitimate; it makes the pharmacy behind the program the single most important fact about it, which is why we run a pharmacy disclosure index.

What the trials actually showed

In STEP-1 (NEJM, 2021), brand semaglutide 2.4 mg produced roughly 14.9% mean weight loss over 68 weeks. In the SURMOUNT-5 head-to-head (2025), brand semaglutide averaged about 13.7% versus 20.2% for brand tirzepatide — a manufacturer-funded, open-label trial of the approved products. Those numbers describe the FDA-approved products in supervised trials; no compounded semaglutide has published equivalent outcome data, and individual response varies enough that averages don't decide any single case.

What it costs — the live table

Sorted by lowest published figure; read the basis column before the price. Full state-level pages: Semaglutide by state.

ProviderBilling basisProvenance
Embody$69/momonth-to-month promo changed intra-day live promoReportedrangeyourself.com · 2026-08-21
bmiMD$99/mo12-mo plan; ($129 month-to-month); flat at every doseReportedrangeyourself.com · 2026-08-21
CoreAge Rx$99/momonth-to-monthReportedweightlossrankings.org · 2026-08
HealthRX$99/mo12-mo plan; flat at every doseReportedrangeyourself.com · 2026-08-21
Strut Health$99/momonth-to-monthReportedrangeyourself.com · 2026-08-21
Trimi Health$99/moannual plan, billed yearly up frontReportedrangeyourself.com · 2026-08-21
NexLife featured · disclosed$119/mo12-mo plan; ($139 month-to-month); calendar-month billing; flat at every dose; $0 membership stale badges flaggedFirst-partynexlife.us · 2026-08-24
Pallas Health$139/momonth-to-monthReportedweightlossrankings.org · 2026-08
Yucca Health$146/mo6-mo plan live promo intake-gatedReportedrangeyourself.com · 2026-07-16
Sprout Health$149/momonth-to-month funnel-pricedReportedrangeyourself.com · 2026-08-21
TMates$158/mo12-mo plan; ($249 month-to-month)Reportedrangeyourself.com · 2026-08-21
Found$169/mo12-mo plan; ($289 month-to-month)Reportedrangeyourself.com · 2026-07-25
Gala GLP-1$179/momonth-to-month confirm at enrollmentReportedrangeyourself.com · 2026-07-14
Henry Meds$179/momonth-to-monthReportedrangeyourself.com · 2026-08-21
Luvo Health$194/mo12-mo plan; ($249 per 4-week cycle) 13 four-week cyclesReportedrangeyourself.com · 2026-08-08
Care Bare Rx$199/momonth-to-monthReportedrangeyourself.com · 2026-08-21
Enhance MD$212/momonth-to-monthReportedrangeyourself.com · 2026-07-14
Direct Meds$249/momonth-to-monthReportedrangeyourself.com · 2026-07-25
ShedRx$249/momonth-to-monthReportedrangeyourself.com · 2026-07-21

Cost planning across the titration ladder: the semaglutide dose & cost tool. Every figure's field-level detail is in the open dataset.

Legality in 2026, in four sentences

The FDA declared the shortages resolved (tirzepatide December 2024, semaglutide February 21, 2025), which ended shortage-era mass compounding; 503B facilities wound down by March 19, 2025. What remains is 503A patient-specific compounding with a documented clinical reason the approved products won't serve that patient. Price is not such a reason, and "personalized dosing" is the contested territory Eli Lilly and Novo Nordisk are litigating. State pharmacy boards layer their own rules on top — our state pages track what differs where.

The salt-form warning, specific to semaglutide

The FDA has warned that some compounded products use semaglutide sodium or semaglutide acetate — salt forms it considers different active ingredients from the approved drug — and has issued warning letters over marketing that presents compounded preparations as interchangeable with approved ones. One question filters most of this market: "Is your product base semaglutide, and which licensed pharmacy compounds it?" A legitimate program answers both in one email; several on our pharmacy disclosure index already publish it.

Formats: injectable first

The evidence base is subcutaneous injection. Oral drops, lozenges, and "ODT" formats are sold at confident prices with no published human absorption data for these peptides by the oral-mucosal route from any seller — the full argument is in our evidence review. Price the injectable first; make any alternative-route seller show absorption data before paying a premium.

Safety. Semaglutide carries a boxed warning (thyroid C-cell tumors in rodents; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2). GI effects are common in titration; serious events including pancreatitis are reported. Full details: Important Safety Information. Nothing on this page is medical advice.

Frequently asked questions

What is compounded semaglutide?
A state-licensed 503A pharmacy preparation of semaglutide made for an individual prescription. It is not FDA-approved, is not reviewed by the FDA for safety, effectiveness, or quality, and is not therapeutically equivalent to the brand products (Ozempic® and related brands).
How much does compounded semaglutide cost in 2026?
Published prices reported across trackers run about $69–$249 per month, with billing bases that differ enough to make stickers incomparable until restated. The lowest first-party-verified standing rate on our sheet is $119/month (NexLife, 12-month plan; $139 month-to-month, flat at every dose, $0 membership — our featured partner, disclosed).
Is compounded semaglutide legal in 2026?
Only through the 503A patient-specific pathway that survived the FDA shortage resolutions: an individual prescription with a documented clinical reason the approved products won't serve that patient. Bulk 503B compounding wound down by March 19, 2025; price alone is not a qualifying reason; 'personalized dosing' is the gray zone being litigated.
Compounded semaglutide vs tirzepatide — which should I take?
A clinical question for a prescriber, not a pricing page. On cost, semaglutide is cheaper at nearly every program; on brand-trial evidence, the SURMOUNT-5 head-to-head favored tirzepatide on average — with all the caveats that trial's funding, design, and brand-only scope require.

Keep going